Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy

Title
Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy
Authors
김순길
Keywords
blood pressure; antihypertensive; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; angiotensin II type 1 receptor; renin-angiotensin-aldosterone system inhibitor
Issue Date
2015-06
Publisher
DOVE MEDICAL PRESS LTD
Citation
DRUG DESIGN DEVELOPMENT AND THERAPY, v. 9, Page. 2847-2854
Abstract
Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ˃= 90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ˃90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88 +/- 8.10 mmHg vs 3.38 +/- 7.33, P=0.0008), and the effect persisted at Week 8 (8.67 +/- 9.39 mmHg vs 5.02 +/- 8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50 +/- 13.76 mmHg vs 5.75 +/- 12.18 mmHg, P=0.0069 and, at Week 8, 13.45 +/- 15.15 mmHg vs 6.84 +/- 13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP. 10 mmHg from baseline and/or a mean siDBP. 90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.
URI
https://www.dovepress.com/efficacy-of-fimasartanhydrochlorothiazide-combination-in-hypertensive--peer-reviewed-article-DDDThttp://hdl.handle.net/20.500.11754/25697
ISSN
1177-8881
DOI
http://dx.doi.org/10.2147/DDDT.S82098
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
Efficacy of fimasartan hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE